SN
PACB icon

Sittner & Nelson’s Pacific Biosciences PACB Stock Holding History

Sittner & Nelson’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$137 – 451
2024
Q2 		$137 Hold
100
– – ﹤0.01% 447
2024
Q1 		$375 Hold
100
– – ﹤0.01% 473
2023
Q4 		$981 Hold
100
– – ﹤0.01% 428
2023
Q3 		$835 Hold
100
– – ﹤0.01% 439
2023
Q2 		$1.33K Buy
100
+40
+67% +$486 ﹤0.01% 449
2023
Q1 		$695 Hold
60
– – ﹤0.01% 469
2022
Q4 		$491 Hold
60
– – ﹤0.01% 446
2022
Q3 		$0 Hold
60
– – ﹤0.01% 480
2022
Q2 		$0 Hold
60
– – ﹤0.01% 479
2022
Q1 		$1K Buy
+60
New +$691 ﹤0.01% 430

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Sittner & Nelson's PACB Position: Q3 2024 in Review

Sittner & Nelson sold out of Pacific Biosciences (PACB) in Q3 2024, closing a stake of 100 shares — an estimated $137 sold.

Sittner & Nelson first reported a position in PACB in Q1 2022 and held it in 10 quarters. The position peaked at $1.33K in Q2 2023. 226 funds tracked by Wall St. Rank hold PACB as of Q3 2024.

  • Sittner & Nelson reported no remaining Pacific Biosciences position as of Q3 2024 after selling out during the quarter.
  • Sittner & Nelson sold 100 Pacific Biosciences shares in Q3 2024, an estimated $137.
  • Sittner & Nelson first reported a position in Pacific Biosciences in Q1 2022 and held it in 10 quarters.
  • Sittner & Nelson's Pacific Biosciences position peaked at $1.33K in Q2 2023.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2024.

Based on Sittner & Nelson's 13F filing for Q3 2024, filed 31 Oct 2024.